NEW YORK (GenomeWeb) – Chinese genetic testing firm Berry Genomics and Illumina have co-developed a next-generation sequencing system and are currently seeking approval for clinical applications from the Chinese Food and Drug Administration, the companies said today.

Under their partnership, the firms have developed a customized sequencer that is based on Illumina's NextSeq 500 and have integrated it with Berry's Bambni noninvasive prenatal test, which includes a PCR-free library prep kit and proprietary RUPATM analysis software.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.